Australia's largest stock trading and investment forum Australia's #1 stock forum

NEU neuren pharmaceuticals limited

0.85%

$12.85

Hi Nashezz, I have a question with regards to the summary Gemini...

First 96 Last

Stonedfish

248 Posts.

82

19/03/25

10:02

Post #: 78323022

Originally posted by nashezz: ↑
I did it out of interest (and so to save Baldy time), here is what Gemini 2.0 Pro said:

(Question was: Can you review the article on this webpage (https://www.biospace.com/drug-devel...ce-heats-up-among-ionis-ultragenyx-and-neuren) and provide a detailed Pro and Con list of the different modalities?)

Okay, let's break down the approaches discussed in that BioSpace article about Angelman Syndrome treatments and analyze the pros and cons of each. The article focuses on three main players (Ionis, Ultragenyx, and Neuren) using different therapeutic modalities.
Here's a detailed Pro and Con list for each:
1. Ionis Pharmaceuticals (and Biogen): Antisense Oligonucleotides (ASOs)
Modality: ASOs are short, synthetic strands of DNA or RNA that can bind to specific mRNA molecules. In Angelman Syndrome, the paternal UBE3A gene is typically silenced due to a functioning maternal UBE3A-AS that produces an antisense transcript, thus inhibiting the translation/expression of UBE3A. ASOs are designed to target and degrade the UBE3A-AS transcript, thereby "unsilencing" the paternal UBE3A gene and allowing it to produce the needed UBE3A protein. The particular drug is known as ION582/BIIB121.
Pros:
Target Specificity: ASOs can be highly specific to their target mRNA sequence, minimizing off-target effects (though these are always a concern).
Proven Technology (in other diseases): ASO technology has been successfully used in other neurological disorders like Spinal Muscular Atrophy (SMA) with Spinraza (nusinersen), providing a degree of validation for the approach.
Potential for Disease Modification: By addressing the underlying genetic cause (silencing of the paternal UBE3A), ASOs offer the potential to be disease-modifying, not just symptom-treating.
Durable Effect: As stated in the article and clinical trial data, the effect is durable.
Cons:
Intrathecal Administration: ASOs typically require intrathecal administration (injection into the spinal fluid), which is an invasive procedure requiring repeated dosing. This carries risks of infection, headache, and other complications.
Potential for Off-Target Effects: While designed for specificity, there's always a risk of ASOs interacting with unintended mRNA sequences, leading to unforeseen side effects.
Immune Response: The body can sometimes mount an immune response against the ASO, reducing its effectiveness or causing inflammation.
Limited CNS Penetration: While intrathecal administration improves delivery to the CNS, distribution throughout the entire brain can still be uneven.
Leg Weakness: As seen in the HALOS trial, leg weakness is a potential, serious side effect.
2. Ultragenyx: GTX-102 (also an ASO)
Modality: Similar to Ionis's approach, GTX-102 is also an antisense oligonucleotide (ASO) designed to target and inhibit the UBE3A-AS transcript, unsilencing the paternal UBE3A gene. The key differences lie in the specific sequence of the ASO and potentially the chemical modifications made to the ASO to enhance stability and reduce side effects.
Pros:
Similar to Ionis's ASO: Shares many of the same potential benefits as Ionis's approach: target specificity, potential for disease modification, and leveraging the proven (in other diseases) ASO platform.
Optimized Dosing (Potentially): Ultragenyx has been working to optimize the dosing regimen to minimize side effects, particularly the leg weakness seen at higher doses. This is a key focus of their ongoing trials.
Durable Effect: Similar to ION582, the effect is durable.
Cons:
Similar to Ionis's ASO: Shares many of the same potential drawbacks: intrathecal administration, potential for off-target effects, immune response, and limited CNS penetration.
Serious Adverse Events: The article highlights that GTX-102 has been associated with serious adverse events, primarily lower extremity weakness, at higher doses. While this appears to be dose-dependent and reversible, it's a significant concern that has led to clinical trial holds and dose adjustments.
Still in Early Development: While promising, GTX-102 is still in relatively early stages of clinical development, and its long-term safety and efficacy profile is still being established.
3. Neuren Pharmaceuticals: NNZ-2591 (trofinetide analog)
Modality: NNZ-2591 is a synthetic analog of a naturally occurring molecule called cyclic glycine-proline (cGP). cGP is a fragment of Insulin-like Growth Factor 1 (IGF-1). IGF-1 plays a crucial role in neuronal development and synaptic function. NNZ-2591 is designed to enhance synaptic function and reduce neuroinflammation. It doesn't directly target the genetic cause of Angelman Syndrome but aims to improve downstream neuronal function.
Pros:
Oral Administration: A major advantage is that NNZ-2591 is orally administered, which is much less invasive than intrathecal injections. This improves patient convenience and reduces the risks associated with spinal taps.
Different Mechanism of Action: Because it doesn't directly target the UBE3A gene, it could potentially be used in combination with other therapies (like ASOs) for a synergistic effect. It also offers an option for patients who might not be suitable candidates for ASO therapy.
Neuroprotective Effects: NNZ-2591's mechanism is thought to have broader neuroprotective effects, potentially addressing multiple aspects of Angelman Syndrome pathophysiology, such as neuroinflammation and synaptic dysfunction.
Positive Phase 2 Data: The article mentions positive results from a Phase 2 trial, suggesting improvements in various clinical measures.
Cons:
Not Disease-Modifying: Unlike ASOs, NNZ-2591 does not address the underlying genetic cause of Angelman Syndrome. It's primarily aimed at improving symptoms and neuronal function, not "curing" the condition.
Less Direct Target: The mechanism of action is less direct than targeting the UBE3A-AS transcript. This could mean that the effects are less potent or more variable between patients.
Long-Term Efficacy Unknown: While Phase 2 results are encouraging, longer-term studies are needed to fully establish the sustained efficacy and safety of NNZ-2591.
May Not Address All Symptoms: Since it's not targeting the root cause, it might not be as effective in addressing all the symptoms of Angelman Syndrome as a gene-targeting approach.
Summary Table:
Column 1 Column 2 Column 3 Column 4
1 Therapy Modality Pros Cons
2 Ionis/Biogen (ION582) ASO Target specificity, potential disease modification, proven technology (in other diseases), durable effect Intrathecal administration, potential off-target effects, immune response, limited CNS penetration, potential leg weakness
3 Ultragenyx (GTX-102) ASO Target specificity, potential disease modification, proven technology (in other diseases), optimized dosing (potentially), durable effect Intrathecal administration, potential off-target effects, immune response, limited CNS penetration, serious adverse events (lower extremity weakness) at high doses
4 Neuren (NNZ-2591) Trofinetide analog (IGF-1) Oral administration, different mechanism of action (potential for combination therapy), neuroprotective effects, positive Phase 2 data Not disease-modifying, less direct target, long-term efficacy unknown, may not address all symptoms
Important Considerations:
Clinical Trial Stage: It's crucial to remember that all these therapies are still under investigation. The information available is based on ongoing clinical trials, and the final risk-benefit profiles are still being determined.
Individual Variability: Patient responses to these treatments are likely to vary, and what works best for one individual may not be the best option for another.
Combination Therapy: The future of Angelman Syndrome treatment may involve combination therapies, using different modalities to target multiple aspects of the disease.
This detailed pro/con list should provide a comprehensive overview of the different treatment approaches discussed in the BioSpace article. Remember to always consult with medical professionals for the most up-to-date and personalized information.
Expand
Hi Nashezz,

I have a question with regards to the summary Gemini 2.0 pro said. towards the bottom in the "Summary table" for Neuren. Column 1, it states (Neuren (NNZ-2591)) then in Column, 2 it states (Trofinetide analog (IGF-1))

aren't NNZ2591 and Trofinetide two totally different molecule's? and why would they both be referenced? or am i confused and mixing up Neuren's drugs or something else?

NEU Price at posting: $12.30 Sentiment: Buy Disclosure: Held

0 Great analysis

Top Stories

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

RCE

Recce locks in $30M to boost commercialisation across ASEAN region

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

First 96 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.85		Change -0.110(0.85%)		Mkt cap ! $1.598B

Open	High	Low	Value	Volume
$12.82	$13.05	$12.53	$6.559M	511.8K

Buyers (Bids)

No.	Vol.	Price($)
1	1657	$12.83

Sellers (Offers)

Price($)	Vol.	No.
$12.85	6303	1

View Market Depth

No.	Vol.	Price($)
1	1657	12.830
2	3312	12.750
1	1224	12.730
3	3229	12.720
1	1299	12.700

Price($)	Vol.	No.
12.850	6303	1
12.890	7731	5
12.910	1229	1
12.920	1474	2
12.950	1299	1

Last trade - 16.10pm 17/06/2025 (20 minute delay)

NEU (ASX) Chart

SPONSORED BY